The FDA has granted Orphan Drug Designation to MacroGenics’ (NASDAQ:MGNX)
margetuximab, an investigational, Fc-engineered monoclonal antibody
targeting HER2 for the treatment of gastric and gastroesophageal
junction cancer.
Among the benefits of Orphan Drug status in the
U.S. is a seven-year period of market exclusivity for the indication, if
approved.
https://seekingalpha.com/news/3580728-macrogenics-margetuximab-orphan-drug-in-u-s-for-gastric-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.